Breaks Categories: Stock Spotlights

MondayJan 30, 2017 12:57 pm

NetworkNewsBreaks – Social Reality, Inc.’s (NASDAQ: SRAX) Real-Time Bidding Solutions Address Rising Demand

Social Reality (NASDAQ: SRAX) is an Internet advertising company providing solutions for automating the digital advertising market. With the real-time bidding market on the rise, the company offers a unique platform to meet this demand. “SRAX, the company’s real-time bidding management platform, allows brands to launch, distribute, track, and optimize their social and digital media and consumer engagement campaigns. This complete solution makes it easier for content creators and owners to get the highest value from demand partners through the SRAX full set of advertising tools.” To view the full article, visit: http://nnw.fm/xz5DW About Social Reality Social Reality, Inc. is…

Continue Reading

FridayJan 27, 2017 2:10 pm

NetworkNewsBreaks – Global Self Storage, Inc. (NASDAQ: SELF) Grows Portfolio, Revenue Streams with Recent Acquisitions

Global Self Storage (NASDAQ: SELF), through its wholly owned subsidiaries, owns and operates a growing number of storage properties in Connecticut, Illinois, Indiana, New York, Ohio, Pennsylvania and South Carolina.  Marking its third and fourth acquisitions in five months, Global Self Storage recently acquired from Tuxis Corporation (OTC: TUXS) two self-storage facilities and a commercial property, bringing its total number of stores to 11. “The addition of these stores is expected to have an immediate accretive impact on our property revenues, net operating income and funds from operations,” company president and CEO Mark C. Winmill stated in the news release.…

Continue Reading

FridayJan 27, 2017 2:07 pm

NetworkNewsBreaks – MGT Capital Investments, Inc. (MGTI) Combats Hacking with Jedi Team

Now that John McAfee, Nolan Bushnell and others have teamed up with MGT Capital Investments, Inc. (OTC: MGTI), the sort of hacking that recently plagued Yahoo!, LinkedIn, and the Democratic National Committee just got a little harder for criminals and state actors alike. The McAfee appellation has become a brand name since John McAfee – now the CEO of MGT Capital - launched the first commercial anti-virus in 1987. Bushnell’s name is similarly well known. The current director of MGT previously founded the video game developer Atari in the early 1970s, which resulted in classic games like Pac-Man and Asteroids.…

Continue Reading

FridayJan 27, 2017 1:54 pm

NetworkNewsBreaks – Inventergy Global, Inc. (NASDAQ: INVT) Focuses on Unparalleled IP Expertise

Intellectual property (IP) has grown from a market mainly accredited to the tech industry to an invaluable component in the legal and business worlds. Corporations are dedicating more resources to ensure their IP assets are managed appropriately in order to meet the growing needs of shareholders. Inventergy Global, Inc. (NASDAQ: INVT) doesn’t just offer corporations greater value from their inventions and ideas, but a partnership led by some of the most experienced professionals in the industry. Founded by Joe Beyers, the previous leader of global licensing for Hewlett-Packard (NYSE: HPE), the company’s team boasts more than 100 years of combined…

Continue Reading

FridayJan 27, 2017 1:49 pm

NetworkNewsBreaks – Lightbridge (NASDAQ: LTBR) Welcomes Renewal of U.S.-Norway 123 Agreement on Commercial Nuclear Energy

The U.S. government recently approved the renewal of a commercial nuclear energy agreement with Norway, a move welcomed by nuclear fuel technology company Lightbridge Corporation (NASDAQ: LTBR). The 123 Agreement legislation was signed in December 2016, following overwhelmingly positive votes by Congress. The legislation also paves the way for Lightbridge to continue research and testing of its metallic nuclear fuel at Norway’s 20 MW Halden research reactor. The innovative, next-generation fuel, made with U.S.-enriched uranium, promises improved safety and economics for nuclear plants, a fact also recognized by the Norwegian Radiation Protection Authority in January this year. On a broader…

Continue Reading

FridayJan 27, 2017 12:15 pm

NetworkNewsBreaks – Novan, Inc. (NASDAQ: NOVN) Shares Plunge on Inconsistent Topline Results from SB204 Phase 3 Pivotal Trials

Novan (NASDAQ: NOVN) shares dropped 75% this morning following the release of top-line results from the two, replicate phase 3 pivotal clinical trials for the company’s topical nitric oxide-releasing product candidate SB204 in the treatment of acne vulgaris. In the intent-to-treat analysis, SB204 demonstrated statistical significance on all three co-primary endpoints in NI-AC302, but it demonstrated statistical significance on only one of three co-primary endpoints in NI-AC301. The three co-primary endpoints included the absolute changes in inflammatory and non-inflammatory lesion counts and proportion of patients achieving success, “clear” or “almost clear,” on the Investigator Global Assessment (IGA) at week 12. …

Continue Reading

ThursdayJan 26, 2017 1:36 pm

NetworkNewsBreaks – Gopher Protocol, Inc. (GOPH) Competes in $1B GPS Personal Tracking Industry with Innovative GuardianPatch

Gopher Protocol (OTCQB: GOPH) develops real-time, self-learning (heuristic) mobile technologies. In collaboration with partner Guardian Patch LLC, Gopher has developed Guardian Patch Location Technology. The company’s patented Integrated Circuit (IC) GopherInsight technology is part of the muscle behind the mobile app designed to track valuables such as electronics or other objects, loved ones or even pets. In November 2016, the GuardianPatch patent was finalized and filed. The product is expected to hit the market in 2017, aligned with the current boom in GPS personal tracking devices and applications, a market expected to break $1 billion in 2017. To learn more,…

Continue Reading

ThursdayJan 26, 2017 1:34 pm

NetworkNewsBreaks – Kindred Biosciences, Inc.’s (NASDAQ: KIN) Strategy to Capture its Share of $7.5B Animal Health Market

Kindred Biosciences (NASDAQ: KIN) is a development-stage biopharmaceutical company taking aim at the $7.5 billion animal health market, specifically focusing on therapies for pets. The company has established a simple, yet effective, strategy to capture its share of the market: leverage investments made in human pharmaceutical R&D to develop therapies that offer the benefits of lower risk, lower cost, and shorter time-to-market. Kindred currently has in development an exciting pipeline of more than 20 programs of high-value products for dogs, cats and horses. The company’s lead candidates are Mirataz™, a weight loss product for cats, and Zimeta™ to treat fever…

Continue Reading

ThursdayJan 26, 2017 1:26 pm

NetworkNewsBreaks – Regulatory Approvals Mark Significant Milestones for Trendlines Group Ltd.’s (TRNLY) Gordian Surgical

Gordian Surgical, a medical portfolio company of Trendlines Group Ltd. (OTCQX: TRNLY), is making significant advances in the way surgical procedures are performed with its TroClose1200™, which in the fourth quarter of 2016 was awarded both U.S. FDA regulatory clearance and CE Mark certification. TroClose1200 was designed to provide surgeons "two-in-one" functionality. The device acts as a trocar, through which surgical instruments enter the abdomen; and as a device to close internal incisions made during surgery. It works by enabling the insertion of sutures into the tissue at the beginning of the procedure and is anchored to remain in place…

Continue Reading

ThursdayJan 26, 2017 1:20 pm

NetworkNewsBreaks – Asterias Biotherapeutics (NYSE: AST): AST-OPC1 Efficacy Results Demonstrate Life-changing Potential for Spinal Cord Injury Patients

With an eye on FDA discussions later this year, biotech Asterias (NYSE: AST) is harnessing the potential of regenerative medicine to improve the quality of life of patients with spinal cord injuries (SCI). Recent efficacy results from the ongoing phase 1/2a clinical trial showed that SCI patients treated with the company’s AST-OPC1 cells demonstrated improved ability to use their arms, hands and fingers. Company CEO Steve Cartt in a press release called the results encouraging as Asterias plans for discussions with the FDA in mid-2017 to determine the appropriate strategy for regulatory approval. According to the World Health Organization, between…

Continue Reading